Barclays
AMLX icon

Barclays’s Amylyx Pharmaceuticals AMLX Stock Holding History

Barclays’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
56,258
-915,596
-94% -$14.2M ﹤0.01% 2786
2026
Q1 		$13.5M Buy
971,854
+676,677
+229% +$9.52M ﹤0.01% 1289
2025
Q4 		$3.57M Sell
295,177
-118,935
-29% -$1.62M ﹤0.01% 2485
2025
Q3 		$5.63M Buy
414,112
+283,838
+218% +$2.67M ﹤0.01% 2101
2025
Q2 		$835K Sell
130,274
-7,131
-5% -$34.7K ﹤0.01% 3457
2025
Q1 		$486K Buy
137,405
+62,560
+84% +$223K ﹤0.01% 3551
2024
Q4 		$283K Sell
74,845
-9,727
-12% -$45.8K ﹤0.01% 4144
2024
Q3 		$274K Buy
84,572
+40,319
+91% +$90.6K ﹤0.01% 4138
2024
Q2 		$84.1K Sell
44,253
-62,589
-59% -$121K ﹤0.01% 3987
2024
Q1 		$303K Buy
106,842
+15,963
+18% +$209K ﹤0.01% 3894
2023
Q4 		$1.34M Buy
90,879
+65,180
+254% +$999K ﹤0.01% 3225
2023
Q3 		$471K Sell
25,699
-52,285
-67% -$1.11M ﹤0.01% 2842
2023
Q2 		$1.68M Sell
77,984
-3,922
-5% -$106K ﹤0.01% 1990
2023
Q1 		$2.4M Buy
81,906
+43,411
+113% +$1.51M ﹤0.01% 2054
2022
Q4 		$1.42M Buy
38,495
+19,695
+105% +$699K ﹤0.01% 2515
2022
Q3 		$529K Buy
18,800
+18,225
+3,170% +$455K ﹤0.01% 2675
2022
Q2 		$11K Sell
575
-984
-63% -$11.7K ﹤0.01% 4588
2022
Q1 		$20K Buy
+1,559
New +$35.2K ﹤0.01% 4438

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Barclays's AMLX Position: Q2 2026 in Review

Barclays reduced its Amylyx Pharmaceuticals (AMLX) stake by 94% in Q2 2026, selling an estimated $14.2M and leaving 56,258 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2786.

Barclays first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $13.5M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Barclays held 56,258 shares of Amylyx Pharmaceuticals worth $1.01M as of Q2 2026.
  • Barclays sold 915,596 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $14.2M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2786 holding.
  • Barclays first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Amylyx Pharmaceuticals position peaked at $13.5M in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.